Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287817 · ClinicalTrials.gov registry record · Phase 1
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
A Phase 1 study, sponsored by Autolus Limited.
- Terminated
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03287817 is a Phase 1 study that was terminated before completion, run by Autolus Limited. The registered enrollment target is 52 participants.
The verdict
NCT03287817, a Phase 1 study, was terminated before completion, sponsored by Autolus Limited.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
Interventions
- BIOLOGICAL AUTO3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-09-05 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287817
The ClinicalTrials.gov registry entry for NCT03287817 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autolus Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AUTO3 is the first listed.
NCT03287817 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03287817 about?
NCT03287817 is a clinical study titled "Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma". The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
What is the current status of trial NCT03287817?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-09-05. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03287817?
The interventions under investigation include: AUTO3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03287817?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.